Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Upbeat On Risperidone Results :: Generics Bulletin
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia - Pharmaceutical Business review
Risperidone extended-release injectable suspension | MDedge Psychiatry
Risperidone extended-release injectable suspension | MDedge Psychiatry
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia
Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror – PharmaLive
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders | SpringerLink
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
PROPOSAL FOR THE ADDITION OF RISPERIDONE LONG-ACTING INJECTION AND PALIPERIDONE PALMITATE 1-MONTH LONG-ACTING INJECTION FOR THE
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders | SpringerLink
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva Pharm Q4 profit rises, sees more growth in key drugs
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
Teva: The Road To Perdition Has Turned Into A Path Towards Redemption (NYSE: TEVA) | Seeking Alpha
Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia
Long-acting injectable antipsychotics: what, when, and how | CNS Spectrums | Cambridge Core
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
